12/4
08:00 am
atos
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
Low
Report
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
12/2
08:00 am
atos
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
Medium
Report
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
11/17
09:22 am
atos
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation [Yahoo! Finance]
Medium
Report
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation [Yahoo! Finance]
11/17
09:07 am
atos
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
Medium
Report
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
11/12
08:38 am
atos
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Low
Report
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
11/12
08:15 am
atos
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Low
Report
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
11/6
08:00 am
atos
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
Low
Report
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
10/24
12:16 pm
atos
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/21
08:00 am
atos
Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
Low
Report
Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
10/15
08:00 am
atos
Atossa Therapeutics to Present at the Maxim Growth Summit 2025
Medium
Report
Atossa Therapeutics to Present at the Maxim Growth Summit 2025
10/14
08:14 am
atos
Atossa Therapeutics appoints CFO to support commercial transition [Seeking Alpha]
Low
Report
Atossa Therapeutics appoints CFO to support commercial transition [Seeking Alpha]
10/14
08:11 am
atos
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness [Yahoo! Finance]
Low
Report
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness [Yahoo! Finance]
10/14
08:00 am
atos
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
Low
Report
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
10/13
08:10 am
atos
Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals [Yahoo! Finance]
Low
Report
Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals [Yahoo! Finance]
10/13
08:00 am
atos
Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
Medium
Report
Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
10/10
05:36 am
atos
Pharma R&D set to endure despite rising MFN costs [Yahoo! Finance]
High
Report
Pharma R&D set to endure despite rising MFN costs [Yahoo! Finance]
10/6
08:08 am
atos
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities [Yahoo! Finance]
Low
Report
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities [Yahoo! Finance]
10/6
08:00 am
atos
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
Neutral
Report
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
10/1
08:44 am
atos
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones [Yahoo! Finance]
Low
Report
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones [Yahoo! Finance]
10/1
08:30 am
atos
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
Medium
Report
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
9/24
07:05 am
atos
Autism by the numbers: Experts share reasons for the dramatic surge in diagnoses [FOX News]
Low
Report
Autism by the numbers: Experts share reasons for the dramatic surge in diagnoses [FOX News]
9/22
08:08 am
atos
Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.50 to $7.75. They now have a "buy" rating on the stock.
Low
Report
Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.50 to $7.75. They now have a "buy" rating on the stock.
9/17
08:00 am
atos
Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
Medium
Report
Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
9/8
08:44 am
atos
Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction [Yahoo! Finance]
Low
Report
Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction [Yahoo! Finance]
9/8
08:30 am
atos
Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
Medium
Report
Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction